influenza
virus
major
concern
public
health
offici
due
potenti
caus
pandem
recent
year
influenza
virus
result
human
ill
result
poultrytohuman
transmiss
present
virus
readili
spread
humantohuman
mutat
andor
reassort
viru
effici
humantohuman
transmiss
could
trigger
influenza
pandem
avian
influenza
viru
current
circul
asia
assum
role
pandem
agent
formid
technic
difficulti
relat
properti
viru
vaccin
product
distribut
administr
would
ensur
vaccin
would
becom
avail
signific
lead
time
low
likelihood
vaccin
would
avail
first
wave
pandem
use
exist
antivir
primarili
oseltamivir
tamiflu
could
critic
initi
control
pandem
although
report
oseltamivir
resist
influenza
infect
patient
drug
resist
influenza
strain
increas
worldwid
evidenc
survey
influenza
field
isol
signific
increas
resist
amantadin
rimantadin
observ
sampl
obtain
asia
sinc
drug
resist
mucos
surfac
serv
entri
site
major
infecti
pathogen
includ
influenza
virus
provid
first
line
defenc
infect
earli
stage
infect
immun
respons
nonantigen
specif
involv
natur
killer
nk
natur
killer
cell
nkt
cell
activ
antigen
present
cell
apc
indirectli
respond
danger
signal
deriv
invad
pathogen
macrophag
dendrit
cell
dc
express
numer
tolllik
receptor
tlr
respond
microbi
pathogen
produc
type
interferon
ifn
cytokin
ten
differ
tlr
bind
specif
class
compound
unmethyl
cpg
dinucleotid
present
bacteri
dna
recogn
singlestrand
ss
rna
virus
vesicular
stomat
viru
influenza
viru
recogn
dsrna
longer
base
pair
produc
viral
replic
cycl
recogn
situat
vaccin
unavail
andor
drug
resist
preval
would
advantag
stimul
immun
system
nonspecif
respond
viral
threat
poli
iclc
dsrna
cpg
odn
molecular
mimic
respect
report
nonspecif
stimul
innat
immun
system
provid
protect
variou
bacteri
viral
pathogen
includ
influenza
address
whether
agent
could
potenti
use
therapeut
agent
vaccin
adjuv
influenza
pandem
aris
need
understand
mechan
action
poli
iclc
cpg
odn
relat
pathogen
effect
influenza
mice
two
dose
mgkgdose
poli
iclc
given
intranas
provid
complet
protect
influenza
viral
challeng
figur
wherea
pretreat
singl
dose
slightli
lower
surviv
rate
compar
studi
demonstr
two
dose
mgkgdose
poli
iclc
effect
two
dose
ukgdos
either
recombin
mous
protect
mice
influenza
infect
surviv
rate
respect
mice
treat
two
dose
poli
iclc
h
apart
prior
viral
challeng
complet
protect
infect
wherea
surviv
rate
decreas
pretreat
given
prior
viru
challeng
respect
increas
surviv
togeth
observ
nk
cell
activ
remain
elev
postpoli
iclc
treatment
liver
bloodspleen
respect
suggest
poli
iclc
may
provid
shortterm
prophylaxi
influenza
outbreak
situat
poli
au
also
increas
nk
cell
activ
liver
approxim
higher
dose
requir
poli
iclc
poli
iclc
abl
provid
protect
mice
infect
rift
valley
fever
viru
provid
mice
given
two
three
intraperiton
ip
dose
one
dose
administ
prior
infect
singl
ip
inject
ampligen
administ
either
h
h
infect
banzi
viru
provid
signific
improv
surviv
comparison
ampligen
administ
prior
infect
semliki
forest
viru
abl
significantli
improv
mortal
given
h
h
prior
infect
poli
iclc
treatment
decreas
number
veevinfect
monkey
becom
detect
virem
delay
onset
viremia
remain
monkey
mice
dose
ip
mgkg
ampligen
h
prior
sarscov
exposur
viral
titr
lung
detect
limit
poli
iclc
administ
follow
influenza
viral
infect
less
effect
administ
prophylact
mice
treat
two
iv
dose
mgkgdose
poli
iclc
h
postinfect
pi
show
small
increas
surviv
rel
untreat
control
mice
postexposur
treatment
singl
dose
found
almost
complet
ineffect
efficaci
postexposur
poli
iclc
treatment
primarili
observ
given
conjunct
preexposur
treatment
efficaci
report
mice
infect
punta
toro
viru
west
nile
viru
treatment
start
prior
infect
continu
everi
h
postinfect
treatment
delay
h
viral
challeng
efficaci
greatli
reduc
treatment
rift
valley
fever
least
four
dose
requir
treatment
start
h
pi
poli
ic
also
use
adjuv
splitproduct
influenza
vaccin
coadministr
poli
ic
primari
booster
dose
vaccin
follow
challeng
influenza
result
crossprotect
administ
variou
viru
vaccin
abeij
ayamagata
partial
protect
heterolog
influenza
vaccin
aguizh
protect
influenza
b
vaccin
bibaraki
byamagata
baichi
tcell
activ
increas
product
observ
mice
immun
homolog
antigen
treatment
vaccin
plu
poli
ic
rapidli
upregul
express
nasalassoci
lymphoid
tissu
upregul
induc
suggest
rout
administr
vaccin
plu
poli
ic
import
trival
inactiv
influenza
vaccin
coadminist
ampligen
provid
crossprotect
variou
strain
influenza
viru
administ
given
subcutan
sc
confirm
import
rout
administr
poli
iclc
adjuv
activ
shown
coadminist
retino
acid
veev
vaccin
antimalari
drug
chloroquin
synerg
poli
iclc
variou
antihiv
compound
includ
cytokin
ser
revers
transcriptas
inhibitor
azidothymidin
phosphonoform
foscarnet
mrna
cap
inhibitor
ribavirin
lipophil
amphotericin
b
glucosidas
inhibitor
castanospermin
observ
similarli
prime
either
poli
ic
complet
block
transient
reduc
west
nile
viru
replic
macrophag
resist
mice
suscept
mice
respect
combin
pretreat
poli
ic
elicit
strong
antivir
respons
complet
prevent
flaviviru
replic
macrophag
suscept
mice
antisemliki
forest
viru
hyperimmun
serum
poli
iclc
given
ip
protect
use
alon
follow
intracrani
semliki
forest
viru
infect
given
togeth
surviv
rate
increas
viremia
viral
load
brain
becam
undetect
phase
studi
poli
iclc
combin
patient
varieti
cancer
show
moder
toxic
poli
iclc
dose
test
increas
peripher
blood
nk
cell
activ
observ
treatment
poli
iclc
alon
high
dose
poli
iclc
combin
result
nk
cell
activ
greater
seen
use
dose
combin
lower
poli
iclc
dose
potenti
poli
iclc
antiinfluenza
agent
howev
limit
intrins
toxic
toxic
poli
iclc
affect
rout
administr
sc
administr
well
toler
rabbit
mice
unpublish
observ
intratrach
administr
well
toler
mice
intranas
intramuscular
im
iv
ip
administr
result
variabl
level
toxic
depend
anim
speci
use
clinic
trial
patient
receiv
multipl
therapeut
dose
poli
iclc
iv
im
exhibit
seriou
toxic
reaction
includ
hypotens
fever
anemia
leukopenia
thrombocytopenia
nausea
inject
site
inflamm
multipl
sclerosi
patient
neurolog
dysfunct
intraarticular
administr
induc
arthriti
mediat
receptor
signal
earli
postadministr
attempt
improv
safeti
efficaci
poli
iclc
focus
optim
dosag
treatment
regim
encapsul
within
liposom
modif
poli
iclc
coadministr
agent
mitig
cytokinemedi
advers
reaction
patient
advanc
cancer
poli
iclc
administ
alternateday
schedul
gradual
dose
escal
toler
best
maximum
toler
dose
vari
sever
hundredfold
dose
rang
mice
poli
iclc
administr
result
loss
total
bodi
weight
hypothermia
mitig
toxic
poli
iclc
without
advers
affect
biolog
activ
poli
iclc
encapsul
within
cation
liposom
compos
phosphatidylcholin
cholesterol
ch
stearylamin
intranas
administr
free
liposomeencapsul
poli
iclc
follow
challeng
lethal
dose
influenza
result
demonstr
reduct
weight
loss
follow
administr
influenza
challeng
magnitud
durat
bodi
temperatur
reduct
reduc
liposomeencapsul
complet
mitig
toxic
determin
absenc
weight
loss
chang
bodi
temperatur
seen
free
poli
iclc
administ
iv
mice
receiv
pretreat
liposomeencapsul
poli
iclc
prior
viru
challeng
fulli
protect
wherea
mice
given
free
poli
iclc
complet
protect
treatment
within
infect
liposom
shown
accumul
site
infect
possibl
concentr
encapsul
drug
diseas
site
therebi
minim
exposur
healthi
organ
tissu
drug
togeth
result
suggest
liposom
encapsul
result
gradual
sustain
releas
poli
iclc
therebi
avoid
rapid
system
elev
drug
level
observ
rout
administr
unclear
whether
signific
reduct
toxic
poli
iclc
provid
liposom
result
correspond
decreas
clinic
side
effect
seen
human
patient
attenu
toxic
side
effect
patient
may
result
increas
drug
toler
improv
clinic
outcom
mitig
cytokinemedi
advers
reaction
attempt
use
signal
pathway
agonist
hydrocortison
treatment
signal
pathway
stimul
poli
iclc
implic
increas
plasma
concentr
male
rat
given
receptor
agonist
prior
poli
ic
administr
elev
plasma
concentr
concomit
reduct
fever
hydrocortison
treatment
prior
follow
iv
poli
iclc
administr
reduc
hypotens
respons
interferon
induct
rabbit
rabbit
mimic
human
febril
hypotens
respons
poli
iclc
thu
would
use
experiment
model
evalu
mechan
approach
reduc
poli
iclc
mediat
toxic
lower
molecular
weight
poli
iclc
abl
gener
high
titer
ifn
amelior
hypotens
respons
rabbit
howev
also
induc
high
fever
select
thiolat
poli
c
strand
five
posit
cytosin
base
gener
partial
thiolat
poli
c
mpc
anneal
complentari
unmodifi
poli
form
thiolat
dsrna
pi
mpc
optim
antivir
antiprolif
activ
obtain
thiolat
result
suggest
studi
modif
poli
iclc
may
advantag
elimin
reduct
toxic
side
effect
current
cpg
odninduc
activ
innat
immun
investig
wide
rang
model
protect
varieti
pathogen
therapeut
activ
cancer
allergi
cpg
odnstimul
immunomodulatori
cascad
peak
persist
sever
week
suggest
cpg
odn
must
administ
earli
prefer
infect
protect
rapidli
lethal
pathogen
wherea
treatment
slowli
grow
pathogen
delay
sever
week
challeng
studi
evalu
efficaci
cpg
odn
influenza
mice
given
ktype
cpg
odn
prior
infect
lethal
dose
influenza
surviv
viral
challeng
wherea
pbstreat
mice
figur
thu
demonstr
cpg
odn
pretreat
efficaci
influenza
viral
infect
cpg
odn
appear
enhanc
immun
respons
even
respons
impair
due
age
diseas
cpg
odn
treatment
splenocyt
senescenceacceler
strain
mice
increas
administr
vivo
gener
virusspecif
cytotox
lymphocyt
respons
nk
cell
activ
virusspecif
ig
isotyp
switch
increas
viral
clearanc
surviv
follow
influenza
viral
challeng
suggest
cpg
odn
could
contribut
develop
protect
strategi
immunocompromis
elderli
person
although
sivinfect
macaqu
detect
product
treatment
dtype
cpg
odn
increas
reduc
leishmania
amazonensisinduc
lesion
treat
wherea
treat
ktype
cpg
odn
reduct
infect
although
cell
prolifer
similar
healthi
macaqu
caution
must
taken
extrapol
anim
studi
human
pbmc
healthi
hivinfect
donor
similar
vitro
respons
k
dtype
cpg
odn
although
magnitud
respons
dtype
cpg
odn
reduc
hivinfect
donor
rel
healthi
donor
clinic
studi
patient
variou
type
b
cell
nonhodgkin
lymphoma
found
b
cell
malign
except
plasmacytoma
respond
cpg
odn
upregul
express
costimulatori
antigenpres
molecul
increas
express
prolifer
although
prolif
respons
less
normal
b
cell
result
suggest
may
possibl
use
cpg
odn
adjuv
expand
potenc
efficaci
antivir
vaccin
popul
risk
yet
least
effect
immun
respons
vaccin
cpg
odn
administ
prior
pathogen
challeng
shown
provid
complet
protect
listeria
monocytogen
francisella
tularensi
herp
simplex
viru
mice
escherichia
coli
chicken
leishmania
major
rhesu
macaqu
cpg
odn
administ
follow
infect
complet
protect
observ
mice
challeng
leishmania
major
complet
protect
also
observ
mycobacterium
tuberculosi
howev
cpg
odn
given
prior
follow
infect
cpg
odn
provid
partial
protect
mice
infect
plasmodium
yoelii
friend
viru
ebola
viru
rml
scrapi
prion
chicken
infect
eimeria
coccidiosi
rhesu
macaqu
infect
leishmania
amazonensi
dispar
result
observ
mice
infect
like
attribut
time
cpg
odn
administr
treatment
h
prior
infect
result
complet
protect
treatment
h
postinfect
result
partial
protect
although
strain
mous
use
could
also
bia
result
balbc
swiss
webster
mice
use
respect
cpg
odn
increas
influenzaspecif
antibodi
product
coadminist
inactiv
influenza
viru
influenza
protein
plasmidbas
vaccin
intranas
deliveri
formalininactiv
influenza
viru
vaccinecpg
odn
mixtur
enhanc
product
antibodi
serum
saliva
genit
tract
sevenfold
higher
antibodi
level
detect
mice
administ
vaccin
cpg
odn
intranas
deliveri
plasmid
dna
encod
influenza
hemagglutinin
ha
administ
without
ktype
cpg
odn
afford
protect
lethal
dose
influenza
survivor
elev
antiha
titr
antiha
titr
also
increas
cpg
odn
treat
mice
coval
linkag
cpg
odn
influenza
viru
ha
result
secret
high
level
ifn
haspecif
antibodi
suggest
crosslink
cpg
odn
peptid
may
effici
adjuv
method
encapsul
cpg
odn
influenza
subunit
vaccin
within
liposom
enhanc
vaccin
potenc
reduc
number
administr
three
twelv
week
postvaccin
mice
treat
liposomeencapsul
vaccin
plu
cpg
odn
time
higher
serum
mucos
iga
level
doubleblind
studi
mg
cpg
odn
coadminist
commerci
trival
kill
split
influenza
vaccin
fluarix
smithklin
beecham
inclus
cpg
odn
increas
antibodi
respons
recipi
compar
fluarix
alon
significantli
increas
antiha
titer
among
subject
preexist
antiinfluenza
antibodi
pbmc
cpg
odnvaccin
subject
respond
vitro
restimul
secret
significantli
higher
level
pbmc
control
vaccine
vaccine
given
cpg
odn
plu
either
full
reduc
dose
fluarix
similar
hemagglutinin
inhibit
antiha
antibodi
titr
antigenspecif
secret
pmbc
decreas
reduc
fluarix
dose
group
suggest
cpg
odn
adjuv
potenti
expand
number
peopl
immun
vaccin
suppli
limit
human
studi
use
cpg
odn
iss
immunostimulatori
dna
sequenc
ktype
cpg
odn
dynavax
technolog
cpg
promun
coley
pharmaceut
conduct
cpg
odn
coadminist
alumabsorb
hbsag
increas
pool
highavid
antibodi
antigen
isotypespecif
manner
coadministr
commerci
hepat
vaccin
energix
b
glaxosmith
kline
gener
protect
level
antihb
antibodi
within
two
week
prime
vaccin
subject
receiv
higher
dose
cpg
odn
higher
rate
posit
cytotox
cell
lymphocyt
respons
phase
clinic
studi
seroprotect
antihbsag
antibodi
titer
observ
singl
dose
rhbsag
plu
mg
iss
subject
wherea
receiv
iss
produc
protect
antibodi
cpg
odn
iss
also
evalu
phase
clinic
studi
adjuv
chimer
monoclon
antibodi
rituximab
genetech
inc
patient
relaps
nonhodgkin
lymphoma
addit
influenza
hepat
b
cpg
odn
also
evalu
adjuv
potenti
protein
vaccin
target
hepat
c
viru
herp
simplex
viru
sarscov
bovin
herpesviru
simian
immunodefici
viru
plasmodium
yoelii
melanoma
antigen
antibodi
therapi
contrast
mice
protocol
immun
human
livestock
requir
higher
dose
cpg
odn
exert
adjuv
activ
advers
event
associ
cpg
odn
coadministr
variou
vaccin
predominantli
shortliv
reaction
ie
pain
erythema
inject
site
flulik
symptom
howev
concern
relat
cpg
odninduc
product
blockad
apoptot
death
activ
lymphocyt
function
predispos
develop
autoimmun
diseas
facilit
persist
selfreact
lymphocyt
rais
studi
found
repeat
inject
immunostimulatori
dose
cpg
dna
appear
induc
acceler
system
autoimmun
diseas
howev
allerg
encephalomyel
autoimmun
myocard
joint
inflamm
overproduct
caus
lifethreaten
toxic
shock
demonstr
immunosuppress
observ
mice
given
high
dose
cpg
odn
daili
sinc
singl
dose
cpg
odn
abl
afford
protect
influenza
would
interest
know
whether
daili
treatment
low
dose
cpg
odn
also
induc
immunosuppress
poli
iclc
liposomeencapsul
cpg
odn
use
reduc
toxic
prolong
exposur
due
gradual
releas
cpg
odn
liposom
mice
treat
liposomeencapsul
cpg
odn
prior
infect
lethal
dose
influenza
surviv
influenza
viral
challeng
lower
weight
loss
faster
recoveri
mice
treat
free
cpg
odn
suggest
liposomeencapsul
decreas
cpg
odn
toxic
cpg
odn
encapsul
within
stabil
antisenselipid
particl
increas
plasma
concentr
monocyt
chemoattract
greater
extent
unencapsul
cpg
odn
encapsul
phosphodiest
cpg
odn
strongli
stimul
cytokin
induct
earli
time
point
suggest
liposomeencapsul
use
decreas
dosag
requir
activ
encapsul
cpg
odn
within
larg
multilamellar
liposom
chang
type
respons
observ
depend
coadminist
mice
coadministr
either
subunit
influenza
vaccin
hbsag
demonstr
mix
respons
influenza
hepat
b
model
respect
cell
lack
prostat
cancer
cell
treatment
phosphorothio
cpg
odn
effect
unless
coadminist
lipofect
transfect
agent
suggest
phosphorothio
cpg
odn
could
also
function
manner
liposomeencapsul
cpg
odn
could
potenti
expand
varieti
cell
type
respond
cpg
odn
codeliveri
cpg
odn
adjuv
antigen
nanospher
also
shown
effici
approach
immun
conjug
odn
ligand
cpg
odn
use
attempt
improv
efficaci
mice
cpg
odnantigen
conjug
inhibit
influenza
viru
effici
coadministr
cpg
odn
antigen
locat
ligand
conjug
import
cpg
odn
reduc
immunostimulatori
activ
compound
conjug
although
conjug
small
molecul
ie
phosphorothio
group
insignific
effect
conjug
odn
ligand
end
cpg
odn
linkag
effect
immunostimulatori
activ
two
cpg
odn
link
term
immunom
synthet
nucleosid
r
bicycl
heterobas
use
replac
c
cpg
dinucleotid
motif
evalu
rpg
odn
immunom
rpg
odn
activ
mitogenactiv
protein
kinas
pathway
rpg
immunom
induc
high
level
time
concentrationdepend
fashion
mous
splenocyt
costimul
significantli
immunom
contain
gtrgtt
gargtt
recogn
similar
extent
mous
human
immun
system
stimul
prolifer
pbmc
prevent
conalbumin
ragwe
allergeninduc
allerg
inflamm
mice
intracellular
tlr
locat
endosom
membran
recogn
ssrna
sequenceindepend
manner
long
rna
contain
sever
uridin
residu
close
proxim
nucleosid
nucleotid
intracellular
pathogen
guanin
nucleosid
analogu
stabil
immunoregulatori
rna
short
dsrna
oligonucleotid
contain
sever
uridin
residu
close
proxim
ie
short
interf
rna
sirna
imidoazoquinolinebas
compound
imiquimod
imq
also
recogn
pdc
primari
produc
cell
follow
exposur
agonist
stimul
result
induct
among
other
singlestrand
rna
induct
also
stimul
autophagi
cellautonom
innat
defenc
mechan
elimin
intracellular
pathogen
macrophag
induct
autophagi
appear
effect
elimin
intracellular
microb
even
target
pathogen
normal
associ
signal
essenti
influenza
viral
recognit
inflammatori
cytokin
product
murin
neutrophil
mice
pretreat
agonist
benzaldehyd
mous
serum
albumin
conjug
prior
influenza
viral
challeng
signific
delay
mortal
rel
receiv
conjug
suggest
stimul
influenzabind
receptor
infect
improv
outcom
intranas
administr
synthet
agonist
significantli
inhibit
influenza
viral
replic
nasal
caviti
rat
administ
h
h
viral
challeng
viral
inhibit
correl
abil
agonist
stimul
type
ifn
cytokin
rat
pbmc
activ
agonist
result
greater
inhibit
viral
titer
compar
rat
recombin
administ
compar
dose
regimen
howev
seriou
concern
relat
stimul
receptor
vivo
studi
system
lupu
erythematosu
sle
mous
model
demonstr
essenti
role
gener
rnacontain
antinuclear
antibodi
deposit
pathogen
immun
complex
kidney
recogn
rna
dnacontain
autoimmun
complex
amplifi
autoimmun
respons
transgen
analysi
determin
modest
increas
express
result
spontan
develop
autoimmun
substanti
increas
express
caus
fatal
acut
inflamm
profound
dc
dysregul
indic
must
tightli
regul
order
prevent
spontan
trigger
harm
autoreact
inflammatori
respons
inhibit
immunoregulatori
sequenc
inhibit
induct
human
pdc
respons
dna
rna
virus
immun
complex
sle
patient
reduc
sle
diseas
sever
human
pbmc
isol
femal
produc
significantli
higher
level
stimul
pbmc
isol
male
although
differ
product
cell
isol
sex
sexdepend
activ
may
explain
higher
preval
sle
femal
report
decreas
therapeut
efficaci
synthet
ligand
male
influenza
highli
contagi
singlestrand
rna
viru
infect
upper
lower
respiratori
tract
human
singlecycl
infect
human
virus
preferenti
infect
noncili
cell
wherea
avian
virus
primarili
infect
ciliat
cell
correl
predomin
local
receptor
human
sialic
acid
avian
sialic
acid
virus
noncili
ciliat
cell
respect
sialic
acid
link
galactos
via
glycosid
bond
cellular
receptor
locat
eye
may
account
ocular
tropism
exhibit
zoonot
avian
influenza
virus
hong
kong
usa
netherland
canada
infiltr
lymphocyt
neutrophil
macrophag
lung
product
reactiv
oxygen
speci
contribut
pulmonari
tissu
damag
observ
influenza
viru
infect
induc
express
varieti
factor
includ
fa
ligand
ifn
regulatori
factor
irf
eotaxin
eosinophil
chemoattract
rant
dsrna
depend
protein
kinas
pkr
indolamin
ido
synthetas
oa
inflammatorymedi
apoptosi
also
induc
produc
cell
specif
influenza
viru
involv
cell
depend
product
nk
cell
suggest
earli
stage
recurr
viral
infect
nk
cellmedi
innat
immun
viru
enhanc
preexist
viru
specif
cell
recent
studi
show
chicken
infect
influenza
viral
strain
resist
influenza
viral
challeng
crossprotect
mediat
cell
bear
tcell
receptor
tcr
subset
protect
immun
close
relat
percentag
cell
express
lung
rather
spleen
suggest
pulmonari
cellular
immun
may
import
protect
natur
host
lethal
influenza
virus
signific
differ
cytokin
respons
influenza
virus
primarili
relat
rant
elev
postinfect
human
type
ii
pneumocyt
significantli
infect
cell
recent
virus
vietnam
potent
induc
compar
studi
use
quantit
pcr
cdna
array
demonstr
virus
induc
much
higher
gene
transcript
proinflammatori
cytokin
particularli
influenza
virus
human
primari
monocytederiv
macrophag
vitro
inactiv
viru
uv
irradi
prior
infect
alveolar
epitheli
cell
abolish
cytokin
induct
suggest
viru
replic
requir
cytokin
induct
transform
growth
factor
potent
proinflammatori
cytokin
activ
monocyt
induc
express
releas
variou
growth
factor
inflammatori
mediat
induc
infect
nonhkorigin
avian
influenza
virus
earli
pi
continu
increas
least
h
contrast
hkorigin
influenza
viru
infect
mice
show
increas
activ
suggest
hk
virus
fail
activ
latent
influenza
infect
bird
system
character
hemorrhag
edema
result
viru
replic
endothelium
system
infect
also
observ
cynomolgu
macaqu
human
vascular
endotheli
growth
factor
vegf
produc
primarili
exclus
alveolar
epitheli
cell
induc
timeand
dosedepend
manner
increas
microvascular
permeabl
contribut
pulmonari
edema
mice
infect
influenza
virusinfect
cell
initi
appear
respiratori
tract
later
could
detect
neuron
glial
ependym
cell
central
nervou
system
influenza
virus
classifi
high
low
pathogen
virus
differ
host
respons
lethal
nonleth
influenza
viru
like
due
nonstructur
ns
protein
mice
infect
lethal
ahong
influenza
viru
signific
decreas
total
number
circul
leukocyt
primarili
lymphocyt
earli
pi
reduct
number
cell
lung
lymphoid
tissu
elev
mice
infect
either
lethal
ahong
nonleth
ahong
influenza
viru
although
degre
elev
lower
mice
infect
lethal
strain
wherea
level
elev
similar
manner
strain
suggest
may
contribut
earli
diseas
sever
wherea
may
play
role
viral
clearanc
late
infect
mice
infect
lethal
influenza
viru
also
increas
concentr
brain
apoptosi
spleen
lung
although
infect
mice
show
evid
virusinduc
enceph
local
synthesi
within
brain
could
contribut
anorexia
weight
loss
death
lethal
influenza
viru
appear
possess
capac
limit
induct
immun
respons
target
destroy
lymphocyt
result
aberr
product
cytokin
serum
tissu
cytokin
storm
addit
cytokin
storm
system
viral
dissemin
alveolar
flood
due
inhibit
cellular
sodium
channel
contribut
lethal
influenza
diseas
human
influenza
viru
mediat
cytokin
storm
character
insensit
antivir
effect
ifn
possibl
due
insuffici
product
increas
concentr
rant
lung
macrophag
mice
decreas
cell
apoptosi
lymphocyt
spleen
lung
detect
cytokin
brain
associ
influenza
patholog
theoret
nonspecif
immun
stimul
effect
influenza
viral
infect
overcom
insensit
ifn
prevent
apoptosi
lymphocyt
without
contribut
cytokin
dysregul
prevent
apoptosi
cell
could
potenti
increas
prefer
would
induc
nonspecif
immun
stimul
alreadi
highli
induc
influenza
viral
infect
although
mice
defici
receptor
reduct
mortal
infect
suggest
alon
respons
increas
mortal
influenza
virus
inhibit
cytokin
respons
corticosteron
natur
mous
glucocorticoid
suffici
prevent
death
regardless
drug
administ
suggest
factor
cytokin
storm
import
lethal
activ
influenza
viru
stimul
cytokin
product
wherea
pathway
distinct
pathway
appear
involv
b
cell
respons
influenza
viru
potent
induct
c
dtype
cpg
odn
human
pdc
b
cell
markedli
reduc
stimul
without
affect
secret
b
cell
prolifer
suggest
neg
feedback
mechan
evolv
could
act
prevent
level
secret
detriment
host
experiment
analysi
sequenti
activ
cell
demonstr
activ
inhibit
activ
vice
versa
suggest
cpg
odn
could
prophylact
agent
influenza
viral
infect
agonist
plu
agonist
presenc
membran
permeabl
enhanc
dotap
addit
effect
respons
human
pbmc
treatment
mice
liposomeencapsul
poli
iclc
evalu
efficaci
influenza
figur
mice
given
one
viru
surviv
rate
wherea
given
two
dose
liposomeencapsul
poli
iclc
surviv
rate
viru
dose
increas
surviv
treat
mice
decreas
wherea
untreat
mice
succumb
infect
demonstr
nonspecif
immun
stimul
may
effect
prophylaxi
pandem
strain
influenza
similar
influenza
viru
respiratori
syncyti
viru
rsv
also
poor
induc
partial
resist
ifn
antivir
activ
poli
iclc
induc
given
rsv
infect
mice
milder
diseas
andor
faster
recoveri
increas
ifn
product
reduc
viral
replic
howev
either
poli
iclc
cpg
odn
administ
h
postrsv
infect
product
almost
complet
inhibit
human
pdc
ifninduc
pathway
abolish
infect
measl
viru
rsv
rsvmediat
effect
attribut
ns
protein
rsv
interfer
activ
essenti
ifn
transcript
factor
yet
demonstr
whether
influenza
affect
signal
pathway
influenza
pandem
occur
age
group
would
affect
influenza
tradit
disproportion
affect
young
elderli
innat
adapt
immun
system
affect
age
innat
immun
system
function
nk
cell
macrophag
fewer
number
less
effici
antigen
present
neutrophil
impair
chemotaxi
degranul
phagocytosi
decreas
age
agerel
chang
adapt
immun
system
includ
diminishedalt
cytokin
pattern
bia
reduct
clonal
expans
function
antigenspecif
b
cell
declin
antigenpres
cell
function
humor
immun
also
exhibit
chang
albeit
lesser
extent
particularli
diminish
abil
gener
highaffin
protect
antibodi
infecti
agent
splenic
activ
periton
macrophag
age
mice
express
significantli
lower
level
tlr
macrophag
age
mice
secret
significantli
lower
level
stimul
known
tlr
ligand
poli
iclc
abl
effect
protect
age
mice
lethal
murin
cytomegaloviru
infect
effect
induc
ifn
immatur
age
mice
treatment
cpg
hasten
matur
dc
recoveryenhanc
type
respons
respect
similarli
immun
compromis
scid
mice
almost
complet
protect
murin
cytomegaloviru
infect
poli
iclc
poli
iclc
abl
induc
ifn
nk
cell
cytotox
mice
result
suggest
although
receptor
reduc
age
process
poli
iclc
cpg
odn
still
potenti
effect
light
current
concern
regard
potenti
influenza
pandem
poli
iclc
cpg
odn
appear
potenti
stimul
innat
immun
system
thu
provid
protect
poli
iclc
stimul
cpg
odn
stimul
would
theoret
effect
adjuv
gener
crossprotect
antibodi
advent
pandem
vaccin
produc
poli
iclc
cpg
odn
adjuv
potenti
thu
expand
number
peopl
could
immun
use
poli
iclc
cpg
odn
adjuv
requir
lower
dose
use
sole
prophylaxi
thu
allevi
toxic
concern
associ
use
poli
ic
cpg
odn
coadministr
demonstr
synergi
nitric
oxid
product
murin
macrophag
vivo
synerg
mediat
paracrineautocrin
effect
bovin
macrophag
dc
also
show
synergist
respons
regard
tnf
product
poli
ic
cpg
odn
coutil
synergi
poli
iclc
cpg
odn
respect
protect
influenza
viral
challeng
either
alon
adjuv
remain
evalu
